
zzso a synthetic zzso zzso has been shown to have substantial zzso activity in zzso and zzso and zzso activity in experimental animal zzso The drug has produced no substantial toxicity in zzso studies and during limited human zzso A phase I clinical trial with this substance was performed at this zzso zzso was administered orally in a single daily zzso The initial starting dose was 30 zzso and, in the absence of zzso subsequent dose levels were reached after zzso zzso Six patients were treated at each dose zzso Forty-eight patients with various zzso zzso tumors zzso with melanoma, breast zzso soft tissue zzso zzso cell zzso and zzso zzso were entered on this zzso No objective zzso were zzso Twelve patients remained stable for periods in excess of 8 zzso No consistent, substantial or zzso toxicity was zzso The maximum tolerated dose was not reached, and dose escalation was stopped at 4,000 zzso as initially zzso With the oral preparation, within this dose range and at this schedule, zzso has no zzso or other zzso zzso 

